Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Harmonex Neuroscience Research

Neither a doctor nor a teaching hospital

Research payments

$724,682

119 payments

Through program year 2025, Harmonex Neuroscience Research is reported as receiving $724,682 in research payments, across 119 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,102 2
2024 Research $38,889 1
2023 Research $35,393 6
2022 Research $1,100 1
2021 Research $8,540 5
2020 Research $331,832 49
2019 Research $304,826 55

Breakdown

Who paid Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $350,836 37 payments
  2. Genentech, Inc. $180,712 20 payments
  3. Supernus Pharmaceuticals, Inc. $56,390 15 payments
  4. Sage Therapeutics, Inc. $41,889 2 payments
  5. AbbVie, Inc. $37,595 8 payments
  6. Hoffmann-La Roche Limited $34,728 7 payments
  7. Rhodes Pharmaceuticals L.P. $13,944 2 payments
  8. H. Lundbeck A S $7,598 6 payments
  9. Pfizer Inc. $990 22 payments
Studies the money was for Research payments · program years 2019–2025
  1. V1a 2 in Pediatric Autism $350,836 37 payments
  2. Phase III Study of Balovaptan in Adults With Asd $180,712 20 payments
  3. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $41,889 2 payments
  4. Study to Assess Scales for RRB in Asd Non Drug Study Digital Biomarker $34,728 7 payments
  5. Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $33,493 6 payments
  6. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $22,462 9 payments
  7. Evaluation of Spn-812 Er 100 and 200 MG Efficacy and Safety in Children With Adhd - A Double-Blind, Placebo- Controlled, Pivotal Trial $19,903 2 payments
  8. A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules Aptensio XR in Children Ages 4-5 Years Diagnosed with Attention-DeficitHyperactivity Disorder ADHD $13,944 2 payments
  9. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficithyperactivity Disorder Adhd $12,006 2 payments
  10. Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) $4,733 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record